Form 8-K - Current report:
SEC Accession No. 0001628280-25-025486
Filing Date
2025-05-14
Accepted
2025-05-14 16:08:18
Documents
15
Period of Report
2025-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K advm-20250514.htm   iXBRL 8-K 25485
2 EX-99.1 exhibit991_51425pressrelea.htm EX-99.1 54490
6 logoa.jpg GRAPHIC 9327
  Complete submission text file 0001628280-25-025486.txt   225033

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT advm-20250514.xsd EX-101.SCH 1782
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT advm-20250514_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT advm-20250514_pre.xml EX-101.PRE 12508
17 EXTRACTED XBRL INSTANCE DOCUMENT advm-20250514_htm.xml XML 2889
Mailing Address 100 CARDINAL WAY REDWOOD CITY CA 94063
Business Address 100 CARDINAL WAY REDWOOD CITY CA 94063 (650) 649-1004
Adverum Biotechnologies, Inc. (Filer) CIK: 0001501756 (see all company filings)

EIN.: 205258327 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36579 | Film No.: 25945478
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)